Why Cellect Biotechnology Shares Are Rising Today

Cellect Biotechnology Ltd APOP is trading higher Monday after the company announced shareholder approval of the strategic merger with Quoin Pharmaceuticals.

Approximately 99% of the votes were in favor of approving the proposal. The strategic merger is expected to close in October.

Cellect Biotechnology is a biotechnology company that has developed a novel technology platform known as ApoGraft that functionally selects cells in order to improve the safety and efficacy of regenerative medicine and cell therapies.

Quoin Pharmaceuticals is a specialty pharmaceutical company focused on rare and orphan diseases.

APOP Price Action: Cellect Biotechnology is making new 52-week highs in trading today.

The stock was up 12.60% at $21.34 at time of publication.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: M&ANewswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!